


AVENIO Oncology Analysis Software

Exceptional performance, minimal effort



Analysis Customer_Analy	Ana 24 4	or 2018 13:3	ed date 0:25 PDT	Ro	bmitted by salind	2.0.0	older location tbcl1/180417_NB	501362_0 A
Analysis name Customer_Analysis	Total	analysis time	e (hh:mm)	Run Tiss	type sue		SNVs	Indole
Analysis ID AF-dDxG1vFtCvp9b9nVa8jC2	02:02		CNVs	Fusio	ons	Sample ID Panel		0
Sample ID Panel	SNVs	Indels			>	xeno-spike1_2 Targeted - A-A2	68	U
Panel xeno.spike1_1 Targeted - A-A1	37	0	2	0	-		7	1
		-	0	0	>	xeno-spike2_2 Targeted - A-B2		
xeno.spike2_1 Targeted - A-B1	71		-	-	1	xeno-spike3_2	▲ 57	1
1	3	1	0	0	1	Targeted - A-C2		
Targeted - A-C1	-							

AVENIO Oncology Analysis Software




The AVENIO Oncology Analysis Software processes sequencing data from plasma and tissue samples run using the AVENIO ctDNA Analysis Kits V2 and AVENIO Tumor Tissue Analysis Kits V2.

The interface guides users confidently through the post-sequencing workflow. Intelligent bioinformatics with advanced proprietary algorithms and error suppression strategies deliver comprehensive results with proven accuracy and reproducibility.^{1,2}

Powerful and intuitive, the AVENIO Oncology Analysis Software offers simplicity, efficiency and accuracy.

For Research Use Only. Not for use in diagnostic procedures.






Set up and run the analysis with ease

The AVENIO Oncology Analysis Software requires minimal expertise to set up and run an analysis. This allows laboratory and bioinformatics professionals to focus more of their time on the findings and insights, and less on managing information systems.

Intuitive user interface:

- Select plasma or tissue
- Offers two user types (Admin, Lab User)
- Provides real-time tracking of analysis status
- Enables filtering, custom annotation, and analytical concordance reporting between tissue and plasma
- Provides reports in PDF format, as well as variant results in VCF and BAM file formats.

With its ability to process approximately 800 million reads in less than a day, the AVENIO Oncology Analysis Software can be set up to run in the evening, delivering results ready for review in the morning.



Detect all four mutation classes in a single DNA workflow

The software's bioinformatic algorithms and checkpoints have been optimized to enable accurate variant calls across all four mutation classes.¹

Detect low frequency alleles with exceptional sensitivity and specificity

The AVENIO Oncology Analysis Software employs integrated digital error suppression (iDES) strategies in the ctDNA workflow, combining molecular barcodes with in silico error suppression techniques. This proprietary method enables detection of low frequency alleles down to 0.1% with exceptional sensitivity and specificity.^{1,2} The tumor tissue workflow employs enzymatic error suppression and molecular barcodes for accurate detection of all four mutation classes from DNA only.

Performance metrics¹

AVENIO ctDNA Ana	Iysis Kits \	/2							
Mutant Allele Frequency/	S	NVs	In	dels	Fus	sions	CN	/s**	
Copy Number	0.5	i% *	1.0	0% *	1.0	0%			
AVENIO Tissue Kit V2	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	
Targeted	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%	
Expanded	>99%	>95%	>99%	>99%	>99%	>99%	SD	>99%	
Surveillance	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%	

SD: Sample dependent; * Detects variants down to 0.1%; **Can detect ERBB2, EGFR and MET CNVs. Performance dependent on input sample type and input concentration(10 ng - 50 ng per reaction). Performance samples: Seraseq ctDNA Complete Mutation Mixes (SeraCare), healthy donor cfDNA. Sensitivity and Positive Predictive Value (PPV) metrics based on observed product performance. Sensitivity and PPV performance reported per variant. Sensitivity was determined using commercially available reference samples containing verified mutations at the stated allele frequencies. SNV performance data based on hotspot calls. The AVENIO ctDNA Analysis Kit V2 can achieve-39.99% per base specificity across each of the panels. Stated performance requires at least 40 million reads per sample for all AVENIO ctDNA Panels V2. Sequencing performed on an Illumia® NextSeqTM 500/550/550Dx instrument.

AVENIO Tumor Tissue Analysis Kits V2

	S	NVs	In	dels	Fu	sions	C	NVs
Mutant Allele Frequency/ Copy Number	50	%*	5	%	5	0/0		
AVENIO ctDNA Kit V2	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV
Targeted	>99%	>99%	>99%	>98%	>99%	>99%	SD	>99%
Expanded	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%
Surveillance	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%

SD: Sample dependent; Samples: FFPE tissue curls/ sections, DNA input: ≥20 ng/ FFPET DNA, total DNA amount for each sample determined by input QC DNA. Sensitivity and Positive Predictive Value (PPV) metrics based on observed product performance. Sensitivity and PPV performance reported per variant. Sensitivity was determined using commercially available reference samples containing verified mutations at the stated allele frequencies. SNV performance based on whitelist variants. AVENIO Tumor Tissue Analysis Kits V2 achieve >99.99% per base specificity across each of the panels. Stated performance requires at least 20 million reads per sample for Targeted. Expanded and Surveillance Kits V2. Sequencing performed on an Illumina[®] NextSeq TM 500/550/550Dx instrument. *L*

-	Sample	-									24 Apr 2018 11:27:59 POT
stomer_/	Analysis > xeno.:	pike1_1									
n.spike1_1		Targeted		Exercise type: Tissue	-	wFilt	ar .			A-A1	orma
014/04	- 3	101.31mg		Callen Internet	special						
Results	Loci of interest	Reports	Output files								
Select filb	er set or report:	144	ewFilter								Show report
-		-	owe use			-			-		39 total variants
SNVs	and indels (37)	CNVs and	fusions (2)								
(Intro)	No.				COSANC TCOA		• silee			E 1100 Gentres Log-of Interest	Dustain
Gene *	Variană 🗄		Venant description	6	AF	4.00	-				
ALK	p.Oly845Dly		Synonymous variant	2	91.30%	٠		٠			
APC	p.Arg348Arg		Synchymous karkan		1.55%	٠		٠			
APC	p.Tyr486Tyr		Synonymous variant	1.1	\$7.62%	٠		٠	÷		
APC	p.Thr1493Thr		Synómymous xarxan		100.00%	٠	•	٠			
APC	p.Pro1960Pro		Synonymous verser		100.00%	٠		٠			
BRAF	p.Gly643Gly		Synónymious karian	1	10.04%	٠			÷		
BRCAT	p Lys1183Arg		Missense variant		7.26%	٠		٠			
BRCAI	p.Pro871Lev		Missense variant		5.29%	٠		٠			
BRCAT	p.Sar694Ser		Synonymous variant		10.11%	٠		٠	+		
BRCA2	p.Asn372Hts		Missense variant		4.17%	٠		٠			
1-10-1	17 Results									- 3	2 5 4 + 4+

HD769 Insting HD769 Insting Userus HVFE Tissue Issue AiA1 HUFE/C1-F3	n Pi_riesC	AMACINES SERVICE 21 Apr 2018 09.4 minute AVENIO FEPET Salari E Pression re A 36.11 De Guerra E 20 Jan 2018	13.04 PDT Targoted Panel ATP
SAMPLE METHICS			
NAMESTI OF FRANCIS	13 M	PRESENT SAMPLE HEADE	68.40%
DEPTH	11793.0 (6482.4 - 23889.3) Messe (01 - 801 percentiles)	-mod torroi	8730 0 (2425.0 - 7762.0) Motor (01) - 001) american
TENOT BATE	7.82+-05	INTERNET BATT	70.67%
TRADUCINE	190 (107 - 375) Mallier (31 - 335 generation)		
Coverage Uni	formity	Allele Fraction	Distribution
	r bas stant stant Salet Those stants & search	Paraditante de	1 - Janet Bartha

Call mutations with confidence

Five leading oncology databases, a curated loci of interest list and a customizable annotation database are integrated into the AVENIO Oncology Analysis Software. This allows quick and easy access to trusted public resources for cross-referencing and verification of results:

- COSMIC
- TCGA
- ExAC
- dbSNP
- 1000 Genomes

These annotation databases can help users call mutations with increased confidence.

Control quality across the workflow

The AVENIO Oncology Analysis Software provides a sequencing quality report with key metrics such as sequencing depth, number of reads, on-target rate, coverage uniformity, and error rate to confirm quality at different stages in the workflow.

For Research Use Only. Not for use in diagnostic procedures.

1. Data on file with Roche.

 Data of the with Fourie.
Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.

Published by:

Roche Sequencing Solutions, Inc. 4300 Hacienda Drive Pleasanton, CA 94588

sequencing.roche.com/avenio

AVENIO is a trademark of Roche. NEXT SEQ is a trademark of Illumina. All other product names and trademarks are the property of their respective owners.